Search Results for:
-
S-LAMININ-MINUS MICE ADD IN VIVO DATA TO MAPPING NEUROMUSCULAR
They transferred this aberrant genomic sequence into embryonic stem cells and inserted these into early- stage fertilized mouse eggs, which they then implanted in the uteri of foster mothersBioWorld Today | Friday, March 17, 1995 -
ALL1 GENE SELF FUSION: A NEW GENETIC MECHANISM IN ACUTE LEUKEMIA
This dreaded disease of the blood occurs when one of the stem cells that gives rise to mature white blood cells mutates...The authors conclude that these structural features indicate that the ALL1 gene may help to regulate the development and differentiation of blood stem cellsBioWorld Today | Thursday, February 23, 1995 -
IMMUNEX SEEKS LEUKINE APPROVAL IN NEW INDICATION
said Tuesday that it filed a product license application (PLA) supplement with the FDA seeking approval to market Leukine for use in peripheral blood stem cell (PBSC) mobilization for transplantation...Valoree Dowell, vice president, corporate communications for Immunex, told BioWorld that 4,000 to 5,000 stem cell transplants were performed in the U.SBioWorld Today | Wednesday, February 15, 1995 -
INTRACELLUAR IMMUNIZATION AGAINST HIV USING RIBOZYMES MOVES CLOSER TO
These scientists used hematopoietic stem cells as their targets for transduction by the ribozyme gene because of their pluripotent nature, thus potentially allowing permanent immune system reconstitution of patients...Macrophage-like cells differentiated from these stem cells in vitro and reproducibly expressed the ribozyme gene at high levelsBioWorld Today | Monday, February 13, 1995 -
OTHER NEWS TO NOTE
Stem Cell Concentration System in Canada. * Gensia Inc., of San Diego, extended an exclusive distribution system with The Laryngeal Mask CoBioWorld Today | Monday, February 13, 1995 -
SANDOZ INVESTS $80M IN SYSTEMIX, INCREASES STAKE TO 72 PERCENT
SyStemix, which focuses mainly on developing cellular and gene therapy products based on hematopoietic stem cells and progenitors, also is collaborating with Sandoz...We remain confident that SyStemix is a leader, or the leader, technologically in stem cell- based cell therapyBioWorld Today | Wednesday, February 1, 1995 -
BAXTER GETS EUROPEAN APPROVAL FOR CELL SEPARATOR
in conjunction with autologous bone marrow and peripheral blood stem cell transplants for the treatment of breast cancer and lymphoma...Baxter's major competitor in the stem cell purification field is CellPro Inc., of Bothell, WashBioWorld Today | Monday, January 23, 1995 -
CELLPRO BEGINS NEW PHASE III OF CEPRATE SYSTEM FOR MYELOMA
has started a Phase III trial of its Ceprate SC stem cell concentration system for a new indication following the FDA's decision earlier this month not to approve the cell purification procedure for autologous bone marrow transplants...The Ceprate SC system is designed to capture and purify CD34 antigen-expressing stem cells, separating them from tumor cells, before the CD34 cells are transplanted back in the patientBioWorld Today | Wednesday, January 18, 1995 -
INTERNEURON PHARMACEUTICALS, SUBSIDIARIES RAISE $8.1M
Progenitor's two core technologies are in the areas of gene therapy vectors and stem cell therapeuticsBioWorld Today | Friday, January 6, 1995 -
CELLPRO'S STOCK DIVES AFTER FDA DELAYS APPROVAL OF STEM CELL PURIFIER
The FDA said CellPro's premarketing approval (PMA) application, submitted in December 1993, must be amended to satisfy various concerns about the stem cell purification system before it can be reconsidered...The Ceparate SC stem cell system targets CD34+ cells, which replicate to form cells of the blood and immune systemBioWorld Today | Wednesday, January 4, 1995 -
ARGUS' ENCAPSULATED RETINOID REMEDY MAKES LEUKEMIA CELLS MATURE HEALTHY
Reasoning that retinoic acid might induce potentially malignant embryonic stem cells to grow up and differentiate into mature white blood cells that don't proliferate out of control, clinicians have administered retinoic acid to cancer patients, with both good and bad resultsBioWorld Today | Tuesday, December 6, 1994 -
OTHER NEWS TO NOTE
Systemix Inc., of Palo Alto, Calif., has received approval from the FDA and European regulatory officials to begin its first clinical trial using purified hematopoietic stem cells to treat myeloma patients...The Phase I/II studies will analyze the treatment's safety and rapid engraftment of the stem cells, which provide all of the cells of the blood and immune systemBioWorld Today | Tuesday, December 6, 1994 -
SPERM CELLS TURN INFERTILE MICE FERTILE, RAISING PROSPECTS FOR
Sperm cells develop from precursor stem-cell spermatogonia, which are "a unique and very fascinating population of cells," Brinster told BioWorld Today...The development of the spermatogonial stem-cell transplantation technique," Dym wrote, "and the possibility of manipulating the genetic makeup of the spermatogonia, provide many potential opportunities for agricultural, biological and medical researchBioWorld Today | Tuesday, November 22, 1994 -
BRITISH BIOTECH STARTS PHASE III BATIMASTAT TRIALS FOR CANCER
with its Stem Cell Chemokine, BB-10010, which is being tested for its ability to mobilize blood cells into peripheral blood and as a protector of stem cells during chemotherapyBioWorld Today | Wednesday, November 16, 1994 -
BRITISH BIOTECH STARTS STEM CELL TRIAL IN CANCER PATIENTS
British Biotech plc completed a safety study of its Stem Cell Chemokine in healthy volunteers and has begun a study in cancer patients, the Oxford, England, company said Monday...The goal would be to harvest stem cells from the bloodstream before chemotherapy and replace then after treatment, potentially replacing bone marrow transplantationBioWorld Today | Tuesday, November 1, 1994 -
GENE THERAPISTS SEE HINT OF SUCCESS AGAINST BLOOD DISORDERS
With this construct, Miller added, "we transduced a group of CD34+ cells, which are a population of bone-marrow progenitor cells that includes stem cellsBioWorld Today | Wednesday, October 19, 1994 -
OTHER NEWS TO NOTE
The company's findings, published in the Oct. 18 issue of Blood, show how facilitating cells permit the engraftment of purified allogeneic bone marrow stem cells without provoking graft-versus-host disease. * Cortecs International Ltd., of London, has signed a worldwide distribution agreement with Germany-based Boehringer Mannheim Diagnostics, a division of Corange Ltd, of London, for Cortecs' immuno sorbent assayBioWorld Today | Wednesday, October 19, 1994 -
TECHNOLOGY TRANSFER CRADA OPPORTUNITY GIBBON VIRUS CLAIMS ADVANTAGES
She added, "Of course, the target cell of most human gene therapy protocols is the human stem cell, and that is not efficiently infected by existing vectorsBioWorld Today | Tuesday, October 18, 1994 -
KNOCKOUT MICE MIMIC TAY-SACHS, BUT DON'T GET SICK
Proia and his co-workers at several NIH institutes crippled the murine Hexa gene in mouse embryonic stem cells, and raised a generation of rodents to serve as biochemical and pathological models for human Tay-SachsBioWorld Today | Wednesday, October 12, 1994 -
GENZYME SIGNS WITH DUTCH COMPANY FOR GAUCHER'S DISEASE
Kathleen Rinehart, Genzyme's spokeswoman, said the collaboration combines IntroGene's stem cell gene therapy with her company's experience with Gaucher's disease, which is caused by the lack of the enzyme, glucocerebrosidase (GCR...IntroGene's technology involves employing a retrovirus to introduce the GCR enzyme into stem cells in the bone marrowBioWorld Today | Friday, October 7, 1994
Category
Current Filters
- xstem cells
Related Keywords
Categories
- x BioWorld Today (3395)
- x BioWorld International (745)
- x BioWorld Insight (683)
- x Bio Perspectives (140)
- x State of the Industry Report (134)
- x BioWorld Snapshots (48)
- x BioWorld Genomics Review (25)
- x Top 25 Drug Report (23)
- x Biotech Innovations (12)
- x Bioscan (6)
- x BioWorld Phase III Report (3)
- x Market-Leading Biotech Drugs (2)
- x RNAi Report (1)
- x MDD (1)
- x Medical Advances (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.